How Tariffs Are Quietly Driving Up Lab Costs
June 10, 2025
Estimated reading time: 3 minutes
If your lab is seeing rising prices for common reagents, solvents, or equipment—without any clear cause—you’re not imagining it. What looks like ordinary inflation is, in many cases, being driven by something else: tariffs.
For years now, global trade disputes and shifting geopolitical alliances have reshaped the cost structure behind the materials labs depend on every day. U.S. tariffs on Chinese goods—especially raw chemicals and intermediate ingredients—have added an invisible cost layer that many labs never see until it shows up in a quote.
Vendors rarely itemize this. There’s no “tariff line” on your invoice. Instead, the impact is baked into base pricing or masked as freight adjustments. Even if you’re not importing directly, you’re feeling the downstream effects—because the products you buy often rely on components or packaging from tariffed regions.
That brings us to a critical update few labs have heard: on May 31, 2025, the Section 301 tariff exemptions that were put in place during the COVID-19 pandemic quietly expired. These exemptions had protected a wide range of lab-critical chemicals and components from full tariff exposure. With no fanfare or headlines, those protections are now gone.
The consequences are immediate. Products that had seen price stability for years are now ticking upward—sometimes subtly, sometimes sharply. Labs operating under strict budgets, federal contracts, or grant funding may be especially vulnerable. A chemical that cost $140 last year might now cost $170, not because of demand or scarcity, but because a tariff exemption quietly disappeared.
The challenge is that most labs haven’t accounted for this in their budgets. Procurement teams may assume rising costs are supplier-driven, or part of normal post-pandemic pricing fluctuations. But the truth is often more complex. And more strategic.
At Rocky Mountain Reagents, we’re seeing more clients asking the right questions:
- How much of this price increase is policy-driven?
- Can we shift to domestic sourcing?
- Which of our SKUs are most exposed to tariff risks?
We welcome those questions. Because the answer isn’t just about cost—it’s about control. We help labs forecast where exposure exists, identify domestic or NAFTA-region options when available, and build pricing agreements that offer stability even in uncertain times.
Here’s what we recommend labs do now:
- Talk to your vendors. Ask what’s changed since May.
- Review any SKUs that have jumped in price by 10% or more.
- Flag products likely to rely on Chinese intermediates.
- Consider locking in long-term pricing where possible.
- Build sourcing plans that include both risk and resilience.
This isn’t about panic. It’s about planning. Tariffs aren’t new—but their effects are intensifying, and they’re hitting quietly. If your lab is still basing decisions on last year’s pricing assumptions, now’s the time to rethink your strategy.
Let’s build procurement plans that are resilient—not just reactive.
